Evidence map›Paper›PMID 35088375›Full record

ArticleMolecular biology reports2022

Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy.

Parisa Zargar, Shabnaz Koochakkhani, Marziyeh Hassanzadeh, Yaghoub Ashouri Taziani, Hamid Nasrollahi, Ebrahim Eftekhar

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Parisa Zargar *Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Shabnaz Koochakkhani *Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Marziyeh Hassanzadeh *Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Yaghoub Ashouri TazianiDepartment of Medical Physics, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Hamid NasrollahiRadio-Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran.
Ebrahim EftekharEndocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. eftekhar19@gmail.com.
Hormozgan University of Medical Sciences · IRShiraz University of Medical Sciences · IR

Funding

Hormozgan University of Medical Sciences 91-F-4
6 · The paper itself

Abstract

backgroundResistance to cisplatin is a major obstacle to effective treatment of bladder cancer (BC). The present study aimed to determine whether a combination of acriflavine (ACF) with cisplatin could potentiate the antitumor property of cisplatin against the BC cells. Furthermore, the molecular mechanism behind the anticancer action of ACF was considered. METHODS AND

resultsTwo human BC cells (5637 and EJ138) contain mutated form of p53 was culture in standard condition. Cotreatment protocol (simultaneous combination of IC

conclusionsOur findings indicate that combination of cisplatin with ACF was able to significantly enhance the sensitivity of BC cells to cisplatin. The antitumor activity of ACF is exerted through the downregulation of TOP1 and TOP2A genes expression. ACF may serve as an adjuvant to boost cisplatin-based chemotherapy.

Indexed as

Antineoplastic AgentsUrinary Bladder NeoplasmsAcriflavineApoptosisCell Line, TumorCisplatinDown-RegulationDrug Resistance, NeoplasmHumansAcriflavineAntineoplastic AgentsCisplatinAcriflavineBladder cancerChemotherapy resistanceCisplatin

Identifiers

PMID35088375
OpenAlexW4210350993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.